Immunotherapy with GcMAF stem cell

http://www.autismtreatment.org.uk/2013/11/27/gcmaf-immunotherapy/



We offer a phone discussion to get to know more about your situation and give you the opportunity to ask the questions that are important to you.




Autism Treatment Plus
t: 07555 744235 (admin)
Out of hours: 075 90 69 87 80
e- admin@autismtreatment.org.uk


Posted by: lorene.amet@gmail.com | Posted on: November 27th, 2013 | 2 Comments



Immunotherapy with GcMAF (Gc protein-derived macrophage activating factor)

Many of you would have heard of GcMAF from Dr Antonucci who presented recently at the Changing the Course of Autism Edinburgh Conference. Dr Antonucci described GcMAF as one of the most successful treatments of autism available to date. GcMAF is the equivalent of the body internal medicine.

What is GcMAF?

GcMAF presents with so much therapeutic potentials that a little explanation about what the molecule does is needed. The Vitamin D-binding receptor (VDR), a Gc-Protein, is the parent molecule of Macrophage Activating Factor termed GcMAF. GcMAF is a powerful immune activator with multiple biological effects, anti-angiogenic and anti-tumorigenic, able to enhance the body’s  immune function through the activation of macrophages, and also capable of directly acting on neurons.

The enzyme Nagalase (α-N-acetylgalactosaminidase) is an important player causing the deregulation of GcMAF function. Nagalase acts by deglycosylation of VDR, thus preventing it from activating macrophages and therefore suppressing the immune response. Nagalase is part of envelope of HIV and is found in cancers, viruses, and HERVs (human endogenous retroviruses). According to Professor Kenny de Meirleir, Nagalase is also found associated with a range of bacterial infections, such as tick-born Borrelia, Bartonella as well as some intestinal bacteria, therefore the elevation of Nagalase does not necessarily indicates a viral infection, it can also means a bacterial infection issue. In any case, it indicates an immune deregulation and suppressed macrophage activities.

Nagalase test

“In this first report of Nagalase activity in patients with autism, it appears that most individuals have substantially higher levels than the expected healthy ranges. Although Nagalase is a nonspecific marker of immune dysregulation, its observed levels in autism may have both etiological and therapeutic significance. Importantly, this is also the first report of reduction of Nagalase activity in an autism population with GcMAF injections.Regardless of any immediate clinical improvement, the reduction of Nagalase to more desirable levels is of potential benefit to these patients, since Nagalase is known to impair immune defences.”…It is noteworthy that vitamin D deficiency, either in pregnancy or during postnatal development, is an apparent risk factor for autism. The impact of Nagalase on VDBP transportation of vitamin D is not known. However, vitamin D deficiency is a known risk factor for autoimmunity.” From: Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections Authors: James Jeffrey Bradstreet, Emar Vogelaar and Lynda Thyer; Publication Date: 10 Dec 2012; Journal: Autism Insights 2012; 4: 31-38.

References

Immunotherapy in chronic diseases

Thyer, Lynda, et al. “THERAPEUTIC EFFECTS OF HIGHLY PURIFIED DE-GLYCOSYLATED GCMAF IN THE IMMUNOTHERAPY OF PATIENTS WITH CHRONIC DISEASES.” American Journal of Immunology 9.3 (2013): 78.

Immunotherapy  in Autism

Hoxhaj, Geranda. “The Combination of the Psycho-Pedagogical Treatment with the Neuro Biochemical Intervention in Children with Autism Spectrum Disorders.” Academic Journal of Interdisciplinary Studies 2.9 (2013): 526.

Immunotherapy in HIV-infected cells

Yamamoto, N., Ushijima, N. and Koga, Y. (2009), Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J. Med. Virol., 81: 16–26. doi: 10.1002/jmv.21376.

Effects of GcMAF in patients with cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis.

Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.
Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini. DOI : 10.3844/ajisp.2013.78.84. American Journal of Immunology. Volume 9, Issue 3. Pages 78-84.

Therapeutic effects of GcMAF in autism About 85% of subjects show improvement following GcMAF treatment.

Initial Observations of elevated Alpha-n-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections. James Jeffrey Bradstreet, emar Vogelaar and Lynda Thyer. Autism Insights 2012:4 31–38. doi: 10.4137/AUI.S10485.

Effects of GcMAF on human neurons explain its therapeutic effects in autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis.

Vitamin D binding protein-derived macrophage activating factor stimulates proliferation and signalling in a human neuronal cell line.
Morucci G, Fiore MG, Magherini S, Branca JJV, Gulisano M, Thyer L, Ruggiero M and Pacini S. Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S143 (P28).

GcMAF has a neuro-protective effect against heavy metal-induced neuronal damage. Implications for autism and chronic fatigue syndrome treatment.

Treatment and Prevention of Cadmium-induced alterations on human neurons. Morucci G, Branca JJV, Ruggiero M, Gulisano M and Pacini S. (P29). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.




leeann grant - Reply
December 9, 2013

is this treatment available from yourselfs ?

im looking to see if this would benefit my son kyle

leeann grant



lorene.amet@gmail.com - Reply
December 9, 2013

Yes it is Leeann, the first stage is to test Nagalase,which requires a blood test. You can contact me for more information, but our nurse is coming on Monday 16th.

Your name: *

Your Email Adress: *

Message: *

Download our brochure AT+ Biomedical



AutismTreatment Plus

Company Limited
Company No.: 08623707

Clinics

Edinburgh
London
Paris
Geneva

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

AT+

Improving the health and development of individuals with autism

ATPlus Twitter

@AutismTreatPlusMarch 2, 2018

fb.me/7iYElOMND

 

@AutismTreatPlusFebruary 21, 2018

fb.me/TcrqzQcy

 

@AutismTreatPlusFebruary 20, 2018

fb.me/xiD8mG2J

 

Newsletter

Email address: